Ligand Pharmaceuticals
LGND
252 hedge funds and large institutions have $2.19B invested in Ligand Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 89 increasing their positions, 97 reducing their positions, and 39 closing their positions.
5.23% more ownership
Funds ownership: 133% → 138.23% (+5.2%)
8% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 97
4% less funds holding
Funds holding: 262 → 252 (-10)
11% less capital invested
Capital invested by funds: $2.47B → $2.19B (-$283M)
23% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 39
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
89% less call options, than puts
Call options by funds: $12.7M | Put options by funds: $120M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$44.7M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$25.1M |
| 3 |
CC
Chicago Capital
Chicago,
Illinois
|
+$23.7M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$21.5M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$27.4M |
| 2 |
Renaissance Technologies
New York
|
-$15.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.1M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$11.3M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$10.8M |
LGND Hedge Fund Activity: Q3 2020 in Review
252 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2020, worth a combined $2.19B — down 11% from $2.47B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of LGND and 30 opened new positions — a net loss of 9 holders — while 97 trimmed existing stakes and 89 added.
The largest buyer was William Blair Investment Management, adding an estimated $44.7M. The largest seller was Ameriprise, cutting an estimated $27.4M.
- 252 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2020, down from 262 in Q2 2020.
- Funds reported $2.19B of Ligand Pharmaceuticals stock for Q3 2020, down 11% quarter-over-quarter.
- 30 funds opened new Ligand Pharmaceuticals positions in Q3 2020 and 39 closed out, a net change of -9 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2020 was William Blair Investment Management, an estimated $44.7M added.
- The largest Ligand Pharmaceuticals seller in Q3 2020 was Ameriprise, an estimated $27.4M sold.
Based on aggregated 13F filings for Q3 2020.